Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152786 · ClinicalTrials.gov registry record · Phase 2
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03152786 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 46 participants.
The verdict
NCT03152786, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Survey Administration
- OTHER Questionnaire Administration
- DRUG Propranolol Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152786
The ClinicalTrials.gov registry entry for NCT03152786 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03152786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152786 about?
NCT03152786 is a clinical study titled "Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery". This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells ...
What is the current status of trial NCT03152786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2019-01-15. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT03152786?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Survey Administration (OTHER), Questionnaire Administration (OTHER), Propranolol Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03152786?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.